Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05652530 is registered in ClinicalTrials.gov with Shenzhen Pregene Biopharma Co., Ltd. as lead sponsor.

NCT NCT05652530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05652530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Shenzhen Pregene Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 13, 2022
Completion date
November 30, 2023
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, multiple myeloma